NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly providing misleading statements about its growth potential and market capabilities, leading to significant investor losses during the specified class period [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Novo securities between May 7, 2025, and July 28, 2025 [2]. - Investors have until September 30, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations Against Novo - The complaint alleges that Novo made overwhelmingly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to Novo's branded alternatives [4]. - The lawsuit claims that Novo overstated its capability to penetrate the GLP-1 market and achieve continued growth [4]. Group 3: Stock Price Impact - Following Novo's announcement on July 29, 2025, regarding lowered sales and profit outlook due to reduced growth expectations, the company's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [5].